Ensaio clínico randomizado sobre o impacto dos macrolídeos na mortalidade de pacientes infectados pelo HIV e com pneumonia adquirida na comunidade
Abstract
Ceftriaxone versus ceftriaxone plus a macrolide for community acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial…………………………………………………………………………29 4. Manuscript 2: Prospective etiological investigation of community-acquired pulmonary infections in hospitalized people living with HIV……………………..49 5. Critical analysis and recommendations…………………………………………71 6. Conclusion…………………………………………………………………………87 Appendix 3. Manuscript 1: Ceftriaxone versus ceftriaxone plus a macrolide for community acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions
- Clinical challenges treatingStenotrophomonas maltophiliainfections: an update
- Guidelines on Implementing Antimicrobial Stewardship Programs in Korea
- Multidrug Resistant Pseudomonas aeruginosa in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies
- What’s old is new again: Insights into diabetic foot microbiome
- Multidrug resistant (or antimicrobial-resistant) pathogens - alternatives to new antibiotics?
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.